XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
ADDITIONAL BALANCE SHEET DETAIL
 3 Months Ended
Mar. 31, 2024
Payables and Accruals [Abstract]  
ADDITIONAL BALANCE SHEET DETAIL ADDITIONAL BALANCE SHEET DETAIL
Prepaid expenses and other current assets are as follows (in thousands):
DescriptionMarch 31, 2024December 31, 2023
Prepaid manufacturing$14,018 $14,489 
Other4,813 5,754 
Total prepaid expenses and other current assets$18,831 $20,243 
See Note 4, Inventories and Prepaid Manufacturing, for further information on prepaid manufacturing expenses.
Other long-term assets are as follows (in thousands):
DescriptionMarch 31, 2024December 31, 2023
Long-term inventories$8,154 $9,403 
Restricted cash1,661 1,654 
Other1,978 1,366 
Total other long-term assets$11,793 $12,423 
See Note 4, Inventories and Prepaid Manufacturing, for further information on long-term inventories.
Cloud Computing Implementation Costs
The Company incurs costs to implement cloud computing arrangements that are hosted by a third-party vendor. In accordance with ASC 350-40, Goodwill and Other, Internal-Use Software, for cloud computing arrangements that meet the definition of a service contract, the Company capitalizes qualifying implementation costs incurred during the application development stage as a component of other assets. Capitalization of these costs concludes once the project is substantially complete and the software is ready for the Company's intended use. Once available for its intended use, the capitalized costs will be amortized on a straight-line basis over the term of the associated hosting arrangement including periods covered by an option to extend, and will be included in selling, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Costs related to data conversion, overhead, general and administrative activities, and training are expensed as incurred. Post-configuration training and maintenance costs will be expensed as incurred.
Other assets as of March 31, 2024 included approximately $0.6 million of capitalized implementation costs. There were no implementation costs capitalized as of December 31, 2023. There was no amortization expense for the three months ended March 31, 2024 and 2023.
Accrued expenses and other current liabilities consists of the following (in thousands): 
Description
March 31, 2024December 31, 2023
Product revenue allowances$13,563 $22,940 
Product return reserves, current portion4,516 5,420 
Clinical trial costs253 328 
Compensation and related benefits5,817 8,216 
Operating lease liabilities, current portion5,071 4,491 
Royalties due to Panion2,568 3,989 
Professional fees2,889 1,909 
Accrued manufacturing costs1,676 5,555 
Restructuring costs, current portion751 737 
BioVectra termination fees, current portion10,000 7,500 
Liability related to sale of future royalties, current portion1,994 2,048 
Other4,812 4,602 
Total accrued expenses and other current liabilities$53,910 $67,735